Australian public assessment for Romidepsin

The safety of pralatrexate was evaluated in 111 peripheral T-cell lymphoma (PTCL) patients in one single-arm pivotal clinical study, PDX-008, in which patients received 30 mg/m2 once weekly for 6 weeks in 7-week cycles. The median duration of treatment was 70 days, with a range of 1 - 696 days. ................
................